Monte Rosa Therapeutics, Inc. (GLUE) — SEC Financial Statements & Analysis

Monte Rosa Therapeutics, Inc. (GLUE) is a biological products, (no diagnostic substances) company, incorporated in DE. Monte Rosa Therapeutics, Inc. trades on Nasdaq as: GLUE. Monte Rosa Therapeutics, Inc. (GLUE)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06. Based on that filing, Monte Rosa Therapeutics, Inc. carries a market cap of $2.46B, a P/E ratio of -15.24x, a P/B ratio of 5.04x, a P/S ratio of 85.49x, an enterprise value of $2.36B, and an EV/EBITDA multiple of -13.59x. On profitability, it posts an operating margin of -633.04%, a net margin of -560.85%, a Return on Equity (ROE) of -42.66%, a Return on Assets (ROA) of -30.67%, and a Return on Invested Capital (ROIC) of -61.64%. Per share, it reports EPS of $-1.59, diluted EPS of $-1.59, free cash flow per share of $-0.32, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -83.86% year-over-year, net income growth of -766.65% year-over-year, and EPS growth of -639.91% year-over-year. On the balance sheet, it maintains a current ratio of 10.58x, a quick ratio of 10.49x, working capital of $571.75M, a debt-to-equity ratio of 0.42x, a debt ratio of 0.29, an interest coverage ratio of -10.14x, free cash flow of $-32.08M (TTM), and net debt of $-95.04M. Figures sourced from SEC EDGAR.

Market Cap

$2.46B

P/E TTM

-15.24x

EPS TTM

$-1.59

P/B TTM

5.04x

ROE TTM

-42.66%

ROA TTM

-30.67%

Debt To Equity

0.42x

Free Cash Flow TTM

$-32.08M

Net Revenue TTM Growth 1Y

-83.86%

Data as of 2026-06-30 · Source: SEC EDGAR